Karachiwala H, Tilley D, Abdel‐Rahman O, et al. - For first‐line treatment in small‐cell lung cancer (SCLC), researchers assessed whether PO vs IV etoposide is useful in combination with a platinum agent (cisplatin/carboplatin) in this study including 2,066 patients with SCLC. Based on stage, patients were divided as limited disease and extensive disease. Route of etoposide administration, dose reductions and vital status was evaluated in chemotherapy naïve patients receiving one cycle of combination chemotherapy. Findings revealed similar overall survival in ES and LS SCLC was afforded by the two dosing routes (PO and IV), however, there was a need for more dose modifications among patients in the PO arm. Based on the findings, PO etoposide could be equivalent to and offer comparable outcomes as IV, and though it may be more toxic, it saved the patients multiple visits to the chemotherapy suite.